Survival

Adverse Impact of Mutations in DNA Methylation Regulatory Genes on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group
James Yu, Jingxin Sun, Yuan Du, Rushang Patel, Juan Carlos Varela, Shahram Mori, Chung-Che Chang
Cite Source Document DOI
Adverse Impact of Mutations in DNA Methylation Regulatory Genes on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group
Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study
James Yu, Yuan Du, Sarfraz Ahmad, Rushang D Patel, Juan Carlos Varela, Chung-Che Chang, Shahram Mori
Cite Source Document DOI
Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study
Adverse Impact of Mutations in DNA Methylation Regulatory Genes on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group
In 2017, the European LeukemiaNet (ELN) stratified AML patients into 3 risk groups based on the presence or absence of specific …
James Yu, Jingxin Sun, Yuan Du, Chung-Che Chang
Cite Source Document DOI
Adverse Impact of Mutations in DNA Methylation Regulatory Genes on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group
Genomic Landscape of Acute Myeloid Leukemia (AML) on the Basis of 2017 ELN Classification and Other Mutations in Adult AML - Single Healthcare System Data
Recently, genomic mutation profiling of leukemic cells has been actively studied and some results have been integrated into the 2017 …
James Yu, Jingxin Sun, Yuan Du, Chung-Che Chang
Cite Source Document DOI
Genomic Landscape of Acute Myeloid Leukemia (AML) on the Basis of 2017 ELN Classification and Other Mutations in Adult AML - Single Healthcare System Data
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma
KRAS mutation subtype is not associated with patient clinical outcomes or PD-L1 expression status. However, PD-L1 positivity appears to negatively affect OS in LADC patients with G12C mutation. Further study is needed to confirm our observation and to determine if programmed cell death 1/PD-L1 antagonist may affect the clinical outcome of patients with different KRAS mutation subtypes.
Luwei Tao, Ruoyu Miao, Tarek Mekhail, Jingxin Sun, Lingbin Meng, Cheng Fang, Jian Guan, Akriti Jain, Yuan Du, Amanda Allen, Brenda L Rzeszutko, Mark A Socinski, Chung-Che Chang
Cite Source Document DOI
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma
The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma
The clinical courses, including tumor stage at diagnosis, presence of brain metastasis, OS and RFS, are similar among lung adenocarcinoma patients with different KRAS mutation subtypes. Additionally, PD-L1 expression status appears to be independent of KRAS mutation subtypes. Of note, concurrent PD-L1 expression and G12C mutation is associated with particularly poorer prognosis. Further study is needed to see if PD1/PD-L1 block may improve outcome of this group of patients.
Luwei Tao, Jingxin Sun, Tarek Mekhail, Lingbin Meng, Yuan Du, Mark A. Socinski, Amanda Allen, Brenda L. Rzeszutko, Chung-Che Chang
Cite Source Document DOI
The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma